IMPORTANCE Nearly half of postmenopausal women report bothersome vulvovaginal symptoms, but few data support the efficacy of 2 commonly recommended treatments.
A n estimated 40% to 54% of postmenopausal women report bothersome vulvovaginal symptoms, [1] [2] [3] including vaginal dryness (up to 75%) and pain with intercourse (40%). 2, 4, 5 In 2014, the North American Menopause Society coined the term genitourinary syndrome of menopause (GSM) to reflect the multifaceted nature of this prevalent problem, replacing genitourinary and vulvovaginal atrophy. 6 Recent evidence shows decrements in quality of life from moderate to severe vulvovaginal symptoms in women aged 40 to 75 years comparable to those caused by other chronic conditions such as arthritis, chronic obstructive pulmonary disease, and irritable bowel syndrome. 1 Yet more than half of symptomatic women are not using any medication to treat their symptoms. 7, 8 Recommendations for treatment of GSM focus primarily on vaginal products.
9,10 However, issues with recommended vaginal treatments include messiness, expense, safety concerns, and lack of symptom relief. 11 In postmenopausal women with vaginal dryness, itching, pain, or burning, metaanalyses of randomized trials conclude that vaginal estrogen cream use reduces symptoms in the majority of women, 12, 13 but few women use them beyond 6 months. 14 Four randomized clinical trials have assessed vaginal estrogen tablet efficacy for GSM, 15-18 but only 2 industry-sponsored trials have evaluated the current 10-μcg product. 15, 17 Although clinicians often recommend vaginal moisturizers, 7 few studies exist to support this recommendation.
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Surveys of postmenopausal women demonstrate a preference for effective, nonhormonal therapies, often due to safety concerns. 22 We aimed to evaluate the efficacy of low-risk therapies: vaginal estradiol tablets and a vaginal moisturizer in women with moderate to severe vulvovaginal symptoms. We hypothesized that the vaginal estradiol tablet is more efficacious than placebo tablet and that a vaginal moisturizer is more efficacious than placebo gel, in the relief of postmenopausal vaginal symptoms.
Methods

Study Design
This randomized, double-blind, placebo-controlled 12-week trial was conducted at 2 centers: Kaiser Permanente Washington Health Research Institute in Seattle and University of Minnesota in Minneapolis. We compared treatment efficacy for moderate to severe vulvovaginal symptoms between 10-μg vaginal estradiol tablets, a vaginal moisturizer, and matching placebos for each. The study was approved by institutional review boards at participating institutions. Participants provided written informed consent. Enrollment began in April 2016, targets were achieved by February 2017, and final follow-up visits occurred in April 2017.
Patient Selection
Women were recruited through direct mailings and Facebook ads targeted to women aged 50 to 70 years within 20 miles of the clinical sites. Inclusion criteria were as follows: age 45 to 70 years, at least 2 years since last menses, report of at least 1 moderate to severe symptom of vulvovaginal itching, pain, irritation, or dryness experienced at least weekly within the past 30 days; or pain with penetration at least once monthly. Exclusion criteria included current vaginal infection, use of hormonal medication in past 2 months, use of antibiotics or vaginal moisturizer in past month, and chronic premenopausal vulvovaginal symptoms. The study protocol (Supplement 1) provides additional details of study procedures.
Randomization by permuted blocks of 9 and stratified by site was conducted via secure web-based database, and implemented by a computerized inventory system for dispensing identical-appearing tablets in bottles and gel in tubes. Participants, study personnel, and clinicians were blinded to treatment assignments.
Interventions
Women were randomly assigned 1:1:1 to Vagifem 10-μg tablet + placebo vaginal gel, placebo vaginal tablet + Replens vaginal moisturizer, or placebo tablet + placebo gel. The active ingredient for tablets is 10.3 μg of estradiol hemihydrate, equivalent to 10 μg of estradiol. Placebo tablets contained inactive ingredients identical to Vagifem. The ingredients in Replens are purified water, glycerin, mineral oil, polycarbophil, carbomer homopolymer type B, hydrogenated palm oil glyceride, sorbic acid, and sodium hydroxide. The placebo was hydroxyethylcellulose gel, shown to have minimal effect on vaginal microbiota and inflammation. 23, 24 Placebo gel varied slightly from Replens in viscosity, 13 800 centipoise, and pH, 4.5 (Replens, 13 000 centipoise and pH 3.0). Study medications were formulated and/or packaged by Sharp Clinical Services. Women were instructed to use the vaginal tablet daily for 2 weeks, then twice weekly for the remaining 10 weeks, and the vaginal moisturizer every 3 days throughout the trial. During the first 2 weeks, participants were advised to use the tablet in the morning and gel in the evening. After that, participants were instructed to use products on alternate days. visit, women completed questionnaires and underwent vaginal sample collection for wet mount evaluation, pH measurement, and vaginal maturation index (VMI, a measure of vaginal mucosal cell maturation due to estrogen effects) 25 (at baseline and 12 weeks). At follow-up visits, women were asked to bring medications; remaining pills were counted and gel tubes weighed to provide medication adherence estimates.
Measurements
The primary outcome was severity of the most bothersome symptom (MBS) defined by the participant at trial enrollment as vulvovaginal itching, pain, dryness, irritation, or pain with penetration. Severity was rated 0 to 3, signifying none, mild, moderate, or severe. Adverse events were assessed at each visit by a questionnaire listing symptoms potentially related to active agents (increased vaginal secretions, vaginal itching, breast tenderness, vaginal bleeding, vulvovaginal skin rash). Any new complaints reported at visits or by telephone were evaluated and classified according to the Medical Dictionary for Regulatory Activities.
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Statistical Analysis
Ninety-five women per group provided 89% power to detect an effect size of 0.5 standard deviation (SD) units change from baseline to week 12 in MBS severity between intervention group and placebo, 19 based on a t test with a 2-sided α = .025 to account for 2 treatment group comparisons. The planned enrollment of 318 participants allowed for 10% loss to followup. The modified intent-to-treat analysis included all randomized participants who provided a baseline MBS score and corresponding vulvovaginal symptom severity at week 4 or 12, regardless of adherence to treatment assignment. The primary outcome was change in severity of the MBS between enrollment and weeks 4 and 12. Treatment group differences were assessed by repeated-measures linear regression models of the 4-and 12-week continuous outcome measures (MBS, VSI, pain with penetration, vaginal dryness, VMI as percent superficial cells, FSFI) as a function of randomization assignment, baseline value of the outcome measure, visit, and clinical site. Robust standard errors were estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. To facilitate comparisons, models of MBS severity were reanalyzed among participants meeting eligibility criteria for previously published trials: baseline pH greater than 5 and VMI with no more than 5% superficial cells. [15] [16] [17] Additional analysis evaluated intervention effects in models including only women adherent to treatment, defined as using at least 80% of medication. Two variables were hypothesized a priori to modify treatment response on the primary outcome: age and years since menopause. Tests for interaction between these variables and treatment assignment were performed within the linear regression models. Treatment group differences at week 12 in proportions of women with medication adherence, at least 2-point drop in MBS severity, at least 50% decrease in MBS severity, vaginal pH of 5 or less, VMI greater than 5% superficial cells, sexual distress, and meaningful benefit from study medication use were assessed via χ 2 tests. Adverse events were compared between treatment groups via Fisher exact tests. Week 12 differences in treatment satisfaction were evaluated by t tests. Analyses were conducted using SAS, version 9.4 (SAS Institute), with 2-sided P ≤ .025 considered statistically significant for the primary outcome and P ≤ .05 for secondary outcomes.
Results
Three hundred two women were randomized to receive vaginal estradiol tablet plus placebo gel (n = 102), placebo tablet plus vaginal moisturizer (n = 100), or dual placebo (n = 100). Study retention was high: 294 of 302 (97%) women provided primary analysis data ( Figure 1 Neither treatment reduced MBS severity between baseline and 4 or 12 weeks more than placebo (Table 2 and Figure 2) . All groups had a mean 1.2-to 1.4-point decrease from baseline MBS score by 12 weeks. A decrease of 2 points signifies a clinically meaningful change from moderate to severe symptoms to mild to none. There was no difference between intervention vs placebo groups in proportion of women with a decrease of at least 2 points in MBS severity between 0 and 12 weeks (estradiol, 47 [49%] Change in FSFI did not significantly vary between treatment groups, either total score or any of the 6 domains ( Table 3) . The FSFI domain with the greatest improvement at 12 weeks was Lubrication, increasing by a mean of 1.4 (95% CI, 1.1-1.8) points in the estradiol + placebo gel group, 1.2 (95% CI, 0.8-1.6) points in dual placebo, and 0.9 (95% CI, 0.6-1.3) points in moisturizer + placebo tablet. Most women were "frequently" or "always" distressed about sex life at enrollment (Table 1) . At 12 weeks, nearly half of women in the estradiol and placebo groups endorsed "rarely" or "never" distressed (47 [47%] estradiol, 29 [29%] moisturizer, 41 [43%] placebo; estradiol vs placebo, P = .50; moisturizer vs placebo, P = .05). Mean (SD) treatment satisfaction was similar between groups: 8.6 (2.6) for estradiol tablet, 7.7 (3.2) for moisturizer, and 8.1 (3.0) for placebo. More women in the estradiol tablet group reported "meaningful benefit" from treatment than placebo (79 [80%] vs 62 [65%]; P = .02), but no difference was observed between moisturizer and placebo (57 [58%] vs 62 [65%]; P = .39).
In regression models including only medicationadherent women, changes in MBS severity and FSFI did not differ from the intent-to-treat analysis (eTables 1 and 2 in Supplement 2). In analysis limited to women meeting enrollment criteria for previous trials of pH greater than 5 and no more than 5% superficial cells on VMI (n = 205), we saw no difference in results. Neither age nor years since menopause modified response to estradiol, although women younger than 60 years demonstrated greater MBS improvement with placebo than with moisturizer (eTable 3 in Supplement 2).
Vaginal candidiasis was diagnosed by microscopy in 5 (5%) participants randomized to estradiol, 2 (2%) to moisturizer, and 2 (2%) to dual placebo. Two additional women reported a yeast infection diagnosed elsewhere. Adverse events were not different between the treatment groups (eTable 4 in Supplement 2). Three women randomized to estradiol received a diagnosis of cancer (all judged unrelated to study medication): 1 with lymphoma at 4 weeks withdrew, 1 with breast cancer at 4 weeks stopped therapy but continued other procedures, and 1 breast cancer diagnosis was made after study completion.
Discussion
In this randomized clinical trial of 302 women with moderate to severe postmenopausal vulvovaginal symptoms, no treatment group differences in symptom reduction were observed for vaginal estradiol tablet plus placebo gel vs dual placebo, or vaginal moisturizer plus placebo tablet vs dual placebo. The lack of efficacy of the active treatment groups over dual placebo was similar whether women chose pain with vaginal penetration, vaginal dryness, or other symptoms as their MBS. We demonstrated similar improvement in symptoms and sexual function in all 3 treatment groups.
The North American Menopause Society recommends nonhormonal vaginal therapies as first-line treatment for GSM, The differential change in VMI in our estradiol group demonstrates the biologic effect of estrogen vs placebo but was not linked to differences in symptom improvement. Overall, the largest difference between our trial and others is the magnitude of symptom improvement in our placebo group. Our placebo was quite different from placebo creams and tablets used in other trials of vaginal estrogen, and meets many of the criteria outlined in a recent review as optimal for vaginal moisturizing products.
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The placebo effect in treatment trials for postmenopausal vaginal symptoms is substantial. In previous trials, placebo tablets were associated with a mean decrease in symptom severity of 0.8 to 0.87 points, 15,17 while placebo softgel was associated with a mean decrease of 1.28 points in dyspareunia severity. 37 In 2 studies of vaginal estrogen cream, dyspareunia severity decreased a mean of 0.7 to 0.9 points in placebo groups. 36,41 The 1.3-point mean symptom severity decrease in our dual placebo group is larger than other trials' placebo effects, with the exception of the softgel study (REJOICE). 37 The symptoms chosen as outcomes for trialsdryness, pain with intercourse, itching, and irritation-are the most commonly reported vulvovaginal symptoms among postmenopausal women, 3-5 and severity is correlated with sexual function scores, suggesting that they are relevant patient outcomes. 42 However, the profound placebo response seen in our trial and others, not linked to changes in pH or VMI, suggests that many factors in addition to the local vaginal environment contribute to symptoms. Many women prescribed vaginal therapy for vulvovaginal symptoms seem unsatisfied with treatment, as continuation rates are low. 44 In previous studies, adherence to tablets was better than vaginal creams. [45] [46] [47] Other reports suggest that women prefer tablet formulation to products that increase discharge or are messy, and would be willing to pay more for a tablet formulation. 48 However, medication cost is a substantial barrier for many women, and hormone-based therapies are expensive. A 1-month supply of vaginal estrogen cream, vaginal estrogen tablets, or newer US Food and Drug Administration-approved products marketed specifically for dyspareunia (ospemifene and vaginal DHEA) can cost between $82 and $200, 49,50 while Replens costs approximately $20. Our results suggest that most women can achieve greater than 50% reduction in symptom severity with regular, consistent use of a vaginal gel with lubricant properties and do not see added symptom improvement with vaginal estradiol.
Limitations
To our knowledge, this is the first randomized clinical trial evaluating short-term (12 weeks) efficacy of recommended nonhormonal and hormonal vaginal therapies for postmenopausal vulvovaginal symptoms, and the only one with a dual placebo arm. We enrolled a large cohort of women with moderate to severe symptoms, with excellent participant retention and medication adherence. While our study was not designed to compare active interventions head to head, efficacy comparisons of vaginal estradiol and moisturizer with dual placebo in the same population provide insight into the relative benefit of each. The generalizability of our trial results is limited by the relatively homogenous population, despite enrolling at 2 geographically distinct sites and using 2 recruitment strategies. Most bothersome symptom severity scores (1 indicates mild; 2, moderate; 3, severe) at 0, 4, and 12 weeks of treatment in women randomized to vaginal estradiol tablet (10 μg) + placebo gel, vaginal moisturizer + placebo tablet, or placebo gel + placebo tablet. Women chose vulvovaginal itching, pain, dryness, irritation, or pain with vaginal penetration as their most bothersome symptom at enrollment. There was no significant difference in the change from baseline in severity scores between treatment groups at 4 or 12 weeks (estradiol vs dual placebo, P = .25; moisturizer vs dual placebo, P = .31).
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Conclusions
Our study demonstrates that a better understanding of the underlying mechanism of GSM is needed to guide efforts to improve vaginal treatment options. Many postmenopausal women with moderate to severe vulvovaginal symptoms can be treated with a nonprescription vaginal lubricating gel. However, not all gel formulations may have the same effects, and some women may prefer nongel formulations. Treatment choice should be based on individual patient preferences regarding cost and formulation. .64 −0.9 (−2.9 to 1.1)
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Week 4 minus baseline a The FSFI is a 19-item questionnaire with a maximum score of 36, which is calculated by adding weighted scores of 6 domains. Higher scores are better, and a score of less than 26 is consistent with sexual dysfunction. Each domain has a maximum score of 6, calculated by multiplying the total score of all questions by a domain factor. sent the results of a randomized, double-blind, placebocontrolled, multisite trial of 2 existing, widely used treatments for postmenopausal vulvovaginal atrophy symptoms-a low-dose prescription vaginal estradiol tablet (Vagifem) and an over-the-counter nonhormonal vaginal moisturizing gel (Replens). Participants were postmenopausal women who rated the severity of their vulvovaginal symptoms including itching, pain, dryness, irritation, and pain with vaginal intercourse on a standardized scale. Consistent with US Food and Drug Administration guidance, the investigators examined change in severity of participants' "most bothersome symptom" over 4 and 12 weeks as the primary outcome, along with a variety of secondary symptom-based outcomes and tissue-specific markers of vulvovaginal atrophy.
At first glance, we might not expect a study that reevaluates low doses of low-risk treatments that have already been studied in clinical trials (albeit with weaknesses) to provide important new insights to guide clinical care. Conventionally, the value of a trial that includes multiple active treatment arms is to compare these treatments directly with each other. In contrast, the present study compared each of the active treatments with matching placebo tablet or placebo gel only, forgoing the opportunity to confirm or exclude a reasonable differential effect between active treatments.
Nevertheless, the investigators argue with some justification that this trial still provides an indirect opportunity to assess the relative efficacy of its active treatments. Women in all treatment arms were selected according to the same eligibility criteria, were recruited from the same 2 clinical sites, and underwent uniform outcomes assessment and follow-up procedures by the same study staff. To date, only very limited prior studies have attempted the simultaneous study of both vaginal estrogen preparations and nonhormonal vaginal treatments, 2-4 with most being too small to draw definitive conclusions and having other limitations such as an open-label design. A rigorous side-by-side assessment of hormonal and nonhormonal vaginal treatments arguably has the potential to provide new insights in clinical care, especially when conducted by investigators without any affiliation with the treatment manufacturers. Furthermore, this design limitation is less concerning in light of the study's striking double-negative finding for both 
